[Chemotherapy of non-small cell bronchial carcinoma].
Non-small cell lung cancer (NSCLC) is less responsive to chemo- and radiotherapy than bronchogenic small cell cancer. Until now the results of chemotherapy in NSCLC have been disappointing. In a retrospective study on epidermoid cell lung cancer we can show that there is no increase of the survival time during the last 22 years. In a total of 2425 patients the median survival time ranged from 179 to 299 days each year, without any trend. Because of the poor therapeutic results and the accompanying toxicity, which deteriorates survival quality, the cytostatic treatment of NSCLC is still an unsolved problem.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy; D003131:Combined Modality Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy
Chemotherapie des nicht-kleinzelligen Bronchuskarzinoms.